Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.
Identifieur interne : 002943 ( PubMed/Checkpoint ); précédent : 002942; suivant : 002944Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.
Auteurs : Tomer Avraham [États-Unis] ; Sanjay Daluvoy ; Jaime Zampell ; Alan Yan ; Yosef S. Haviv ; Stanley G. Rockson ; Babak J. MehraraSource :
- The American journal of pathology [ 1525-2191 ] ; 2010.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (pharmacologie), Cellules cultivées, Cicatrisation de plaie (), Cicatrisation de plaie (immunologie), Cicatrisation de plaie (physiologie), Facteur de croissance transformant bêta-1 (antagonistes et inhibiteurs), Facteur de croissance transformant bêta-1 (immunologie), Facteur de croissance transformant bêta-1 (métabolisme), Femelle, Fibrose (anatomopathologie), Humains, Lymphangiogenèse (), Lymphangiogenèse (immunologie), Lymphangiogenèse (physiologie), Lymphocytes auxiliaires Th2 (), Lymphocytes auxiliaires Th2 (physiologie), Lymphoedème (anatomopathologie), Lymphoedème (immunologie), Lymphoedème (métabolisme), Régulation positive (), Régulation positive (immunologie), Régulation positive (physiologie), Régénération (), Régénération (immunologie), Régénération (physiologie), Souris, Souris de lignée C57BL, Vaisseaux lymphatiques (), Vaisseaux lymphatiques (immunologie), Vaisseaux lymphatiques (métabolisme), Vaisseaux lymphatiques (physiopathologie).
- MESH :
- anatomopathologie : Fibrose, Lymphoedème.
- antagonistes et inhibiteurs : Facteur de croissance transformant bêta-1.
- immunologie : Cicatrisation de plaie, Facteur de croissance transformant bêta-1, Lymphangiogenèse, Lymphoedème, Régulation positive, Régénération, Vaisseaux lymphatiques.
- métabolisme : Facteur de croissance transformant bêta-1, Lymphoedème, Vaisseaux lymphatiques.
- pharmacologie : Anticorps monoclonaux.
- physiologie : Cicatrisation de plaie, Lymphangiogenèse, Lymphocytes auxiliaires Th2, Régulation positive, Régénération.
- physiopathologie : Vaisseaux lymphatiques.
- Animaux, Cellules cultivées, Cicatrisation de plaie, Femelle, Humains, Lymphangiogenèse, Lymphocytes auxiliaires Th2, Régulation positive, Régénération, Souris, Souris de lignée C57BL, Vaisseaux lymphatiques.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (pharmacology), Cells, Cultured, Female, Fibrosis (pathology), Humans, Lymphangiogenesis (drug effects), Lymphangiogenesis (immunology), Lymphangiogenesis (physiology), Lymphatic Vessels (drug effects), Lymphatic Vessels (immunology), Lymphatic Vessels (metabolism), Lymphatic Vessels (physiopathology), Lymphedema (immunology), Lymphedema (metabolism), Lymphedema (pathology), Mice, Mice, Inbred C57BL, Regeneration (drug effects), Regeneration (immunology), Regeneration (physiology), Th2 Cells (drug effects), Th2 Cells (physiology), Transforming Growth Factor beta1 (antagonists & inhibitors), Transforming Growth Factor beta1 (immunology), Transforming Growth Factor beta1 (metabolism), Up-Regulation (drug effects), Up-Regulation (immunology), Up-Regulation (physiology), Wound Healing (drug effects), Wound Healing (immunology), Wound Healing (physiology).
- MESH :
- chemical , antagonists & inhibitors : Transforming Growth Factor beta1.
- chemical , immunology : Transforming Growth Factor beta1.
- chemical , metabolism : Transforming Growth Factor beta1.
- chemical , pharmacology : Antibodies, Monoclonal.
- drug effects : Lymphangiogenesis, Lymphatic Vessels, Regeneration, Th2 Cells, Up-Regulation, Wound Healing.
- immunology : Lymphangiogenesis, Lymphatic Vessels, Lymphedema, Regeneration, Up-Regulation, Wound Healing.
- metabolism : Lymphatic Vessels, Lymphedema.
- pathology : Fibrosis, Lymphedema.
- physiology : Lymphangiogenesis, Regeneration, Th2 Cells, Up-Regulation, Wound Healing.
- physiopathology : Lymphatic Vessels.
- Animals, Cells, Cultured, Female, Humans, Mice, Mice, Inbred C57BL.
Abstract
Lymphedema is a complication of cancer treatment occurring in approximately 50% of patients who undergo lymph node resection. Despite its prevalence, the etiology of this disorder remains unknown. In this study, we determined the effect of soft tissue fibrosis on lymphatic function and the role of transforming growth factor (TGF)-β1 in the regulation of this response. We determined TGF-β expression patterns in matched biopsy specimens collected from lymphedematous and normal limbs of patients with secondary lymphedema. To determine the role of TGF-β in regulating tissue fibrosis, we used a mouse model of lymphedema and inhibited TGF-β function either systemically with a monoclonal antibody or locally by using a soluble, defective TGF-β receptor. Lymphedematous tissue demonstrated a nearly threefold increase in the number of cells that stained for TGF-β1. TGF-β inhibition markedly decreased tissue fibrosis, increased lymphangiogenesis, and improved lymphatic function compared with controls. In addition, inhibition of TGF-β not only decreased TGF-β expression in lymphedematous tissues, but also diminished inflammation, migration of T-helper type 2 (Th2) cells, and expression of profibrotic Th2 cytokines. Similarly, systemic depletion of T-cells markedly decreased TGF-β expression in tail tissues. Inhibition of TGF-β function promoted lymphatic regeneration, decreased tissue fibrosis, decreased chronic inflammation and Th2 cell migration, and improved lymphatic function. The use of these strategies may represent a novel means of preventing lymphedema after lymph node resection.
DOI: 10.2353/ajpath.2010.100594
PubMed: 21056998
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:21056998Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.</title>
<author><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Daluvoy, Sanjay" sort="Daluvoy, Sanjay" uniqKey="Daluvoy S" first="Sanjay" last="Daluvoy">Sanjay Daluvoy</name>
</author>
<author><name sortKey="Zampell, Jaime" sort="Zampell, Jaime" uniqKey="Zampell J" first="Jaime" last="Zampell">Jaime Zampell</name>
</author>
<author><name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name>
</author>
<author><name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name>
</author>
<author><name sortKey="Rockson, Stanley G" sort="Rockson, Stanley G" uniqKey="Rockson S" first="Stanley G" last="Rockson">Stanley G. Rockson</name>
</author>
<author><name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:21056998</idno>
<idno type="pmid">21056998</idno>
<idno type="doi">10.2353/ajpath.2010.100594</idno>
<idno type="wicri:Area/PubMed/Corpus">002850</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002850</idno>
<idno type="wicri:Area/PubMed/Curation">002850</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002850</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002850</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002850</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.</title>
<author><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Daluvoy, Sanjay" sort="Daluvoy, Sanjay" uniqKey="Daluvoy S" first="Sanjay" last="Daluvoy">Sanjay Daluvoy</name>
</author>
<author><name sortKey="Zampell, Jaime" sort="Zampell, Jaime" uniqKey="Zampell J" first="Jaime" last="Zampell">Jaime Zampell</name>
</author>
<author><name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name>
</author>
<author><name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name>
</author>
<author><name sortKey="Rockson, Stanley G" sort="Rockson, Stanley G" uniqKey="Rockson S" first="Stanley G" last="Rockson">Stanley G. Rockson</name>
</author>
<author><name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name>
</author>
</analytic>
<series><title level="j">The American journal of pathology</title>
<idno type="eISSN">1525-2191</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Cells, Cultured</term>
<term>Female</term>
<term>Fibrosis (pathology)</term>
<term>Humans</term>
<term>Lymphangiogenesis (drug effects)</term>
<term>Lymphangiogenesis (immunology)</term>
<term>Lymphangiogenesis (physiology)</term>
<term>Lymphatic Vessels (drug effects)</term>
<term>Lymphatic Vessels (immunology)</term>
<term>Lymphatic Vessels (metabolism)</term>
<term>Lymphatic Vessels (physiopathology)</term>
<term>Lymphedema (immunology)</term>
<term>Lymphedema (metabolism)</term>
<term>Lymphedema (pathology)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Regeneration (drug effects)</term>
<term>Regeneration (immunology)</term>
<term>Regeneration (physiology)</term>
<term>Th2 Cells (drug effects)</term>
<term>Th2 Cells (physiology)</term>
<term>Transforming Growth Factor beta1 (antagonists & inhibitors)</term>
<term>Transforming Growth Factor beta1 (immunology)</term>
<term>Transforming Growth Factor beta1 (metabolism)</term>
<term>Up-Regulation (drug effects)</term>
<term>Up-Regulation (immunology)</term>
<term>Up-Regulation (physiology)</term>
<term>Wound Healing (drug effects)</term>
<term>Wound Healing (immunology)</term>
<term>Wound Healing (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps monoclonaux (pharmacologie)</term>
<term>Cellules cultivées</term>
<term>Cicatrisation de plaie ()</term>
<term>Cicatrisation de plaie (immunologie)</term>
<term>Cicatrisation de plaie (physiologie)</term>
<term>Facteur de croissance transformant bêta-1 (antagonistes et inhibiteurs)</term>
<term>Facteur de croissance transformant bêta-1 (immunologie)</term>
<term>Facteur de croissance transformant bêta-1 (métabolisme)</term>
<term>Femelle</term>
<term>Fibrose (anatomopathologie)</term>
<term>Humains</term>
<term>Lymphangiogenèse ()</term>
<term>Lymphangiogenèse (immunologie)</term>
<term>Lymphangiogenèse (physiologie)</term>
<term>Lymphocytes auxiliaires Th2 ()</term>
<term>Lymphocytes auxiliaires Th2 (physiologie)</term>
<term>Lymphoedème (anatomopathologie)</term>
<term>Lymphoedème (immunologie)</term>
<term>Lymphoedème (métabolisme)</term>
<term>Régulation positive ()</term>
<term>Régulation positive (immunologie)</term>
<term>Régulation positive (physiologie)</term>
<term>Régénération ()</term>
<term>Régénération (immunologie)</term>
<term>Régénération (physiologie)</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Vaisseaux lymphatiques ()</term>
<term>Vaisseaux lymphatiques (immunologie)</term>
<term>Vaisseaux lymphatiques (métabolisme)</term>
<term>Vaisseaux lymphatiques (physiopathologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Transforming Growth Factor beta1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Transforming Growth Factor beta1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Transforming Growth Factor beta1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Fibrose</term>
<term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance transformant bêta-1</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphangiogenesis</term>
<term>Lymphatic Vessels</term>
<term>Regeneration</term>
<term>Th2 Cells</term>
<term>Up-Regulation</term>
<term>Wound Healing</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cicatrisation de plaie</term>
<term>Facteur de croissance transformant bêta-1</term>
<term>Lymphangiogenèse</term>
<term>Lymphoedème</term>
<term>Régulation positive</term>
<term>Régénération</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lymphangiogenesis</term>
<term>Lymphatic Vessels</term>
<term>Lymphedema</term>
<term>Regeneration</term>
<term>Up-Regulation</term>
<term>Wound Healing</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphatic Vessels</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de croissance transformant bêta-1</term>
<term>Lymphoedème</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Fibrosis</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Cicatrisation de plaie</term>
<term>Lymphangiogenèse</term>
<term>Lymphocytes auxiliaires Th2</term>
<term>Régulation positive</term>
<term>Régénération</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lymphangiogenesis</term>
<term>Regeneration</term>
<term>Th2 Cells</term>
<term>Up-Regulation</term>
<term>Wound Healing</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Lymphatic Vessels</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cells, Cultured</term>
<term>Female</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules cultivées</term>
<term>Cicatrisation de plaie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphangiogenèse</term>
<term>Lymphocytes auxiliaires Th2</term>
<term>Régulation positive</term>
<term>Régénération</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphedema is a complication of cancer treatment occurring in approximately 50% of patients who undergo lymph node resection. Despite its prevalence, the etiology of this disorder remains unknown. In this study, we determined the effect of soft tissue fibrosis on lymphatic function and the role of transforming growth factor (TGF)-β1 in the regulation of this response. We determined TGF-β expression patterns in matched biopsy specimens collected from lymphedematous and normal limbs of patients with secondary lymphedema. To determine the role of TGF-β in regulating tissue fibrosis, we used a mouse model of lymphedema and inhibited TGF-β function either systemically with a monoclonal antibody or locally by using a soluble, defective TGF-β receptor. Lymphedematous tissue demonstrated a nearly threefold increase in the number of cells that stained for TGF-β1. TGF-β inhibition markedly decreased tissue fibrosis, increased lymphangiogenesis, and improved lymphatic function compared with controls. In addition, inhibition of TGF-β not only decreased TGF-β expression in lymphedematous tissues, but also diminished inflammation, migration of T-helper type 2 (Th2) cells, and expression of profibrotic Th2 cytokines. Similarly, systemic depletion of T-cells markedly decreased TGF-β expression in tail tissues. Inhibition of TGF-β function promoted lymphatic regeneration, decreased tissue fibrosis, decreased chronic inflammation and Th2 cell migration, and improved lymphatic function. The use of these strategies may represent a novel means of preventing lymphedema after lymph node resection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21056998</PMID>
<DateCreated><Year>2010</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>03</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>177</Volume>
<Issue>6</Issue>
<PubDate><Year>2010</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of pathology</Title>
<ISOAbbreviation>Am. J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.</ArticleTitle>
<Pagination><MedlinePgn>3202-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2353/ajpath.2010.100594</ELocationID>
<Abstract><AbstractText>Lymphedema is a complication of cancer treatment occurring in approximately 50% of patients who undergo lymph node resection. Despite its prevalence, the etiology of this disorder remains unknown. In this study, we determined the effect of soft tissue fibrosis on lymphatic function and the role of transforming growth factor (TGF)-β1 in the regulation of this response. We determined TGF-β expression patterns in matched biopsy specimens collected from lymphedematous and normal limbs of patients with secondary lymphedema. To determine the role of TGF-β in regulating tissue fibrosis, we used a mouse model of lymphedema and inhibited TGF-β function either systemically with a monoclonal antibody or locally by using a soluble, defective TGF-β receptor. Lymphedematous tissue demonstrated a nearly threefold increase in the number of cells that stained for TGF-β1. TGF-β inhibition markedly decreased tissue fibrosis, increased lymphangiogenesis, and improved lymphatic function compared with controls. In addition, inhibition of TGF-β not only decreased TGF-β expression in lymphedematous tissues, but also diminished inflammation, migration of T-helper type 2 (Th2) cells, and expression of profibrotic Th2 cytokines. Similarly, systemic depletion of T-cells markedly decreased TGF-β expression in tail tissues. Inhibition of TGF-β function promoted lymphatic regeneration, decreased tissue fibrosis, decreased chronic inflammation and Th2 cell migration, and improved lymphatic function. The use of these strategies may represent a novel means of preventing lymphedema after lymph node resection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avraham</LastName>
<ForeName>Tomer</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Daluvoy</LastName>
<ForeName>Sanjay</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zampell</LastName>
<ForeName>Jaime</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yan</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Haviv</LastName>
<ForeName>Yosef S</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rockson</LastName>
<ForeName>Stanley G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mehrara</LastName>
<ForeName>Babak J</ForeName>
<Initials>BJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>T32 CA009501</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA08748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R24 CA83084</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 CA 009501</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R24 CA083084</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>11</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Pathol</MedlineTA>
<NlmUniqueID>0370502</NlmUniqueID>
<ISSNLinking>0002-9440</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 2007 Nov;87(11):1077-91</RefSource>
<PMID Version="1">17724448</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 1998 Nov;102(6):1805-17; discussion 1818-20</RefSource>
<PMID Version="1">9810974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1990 Jul 26;346(6282):371-4</RefSource>
<PMID Version="1">2374609</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1990 Aug;86(2):453-62</RefSource>
<PMID Version="1">2200803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 1991 Aug;97(2):240-8</RefSource>
<PMID Version="1">2071936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 1991 Aug;14(2):269-73</RefSource>
<PMID Version="1">1713566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Surv. 1992;12:81-103</RefSource>
<PMID Version="1">1638549</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 1993 Feb;68(2):154-63</RefSource>
<PMID Version="1">8441250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1993 Dec;92(6):2597-601</RefSource>
<PMID Version="1">8254017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1994 Jul 15;153(2):753-9</RefSource>
<PMID Version="1">8021510</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1994 Jul;145(1):105-13</RefSource>
<PMID Version="1">8030742</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 1995 Jan;21(1):113-9</RefSource>
<PMID Version="1">7806143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer Care (Engl). 1995 Mar;4(1):11-6</RefSource>
<PMID Version="1">7620649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1995 Aug 1;155(3):1544-55</RefSource>
<PMID Version="1">7636216</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Plast Surg. 2000 May;44(5):522-8</RefSource>
<PMID Version="1">10805304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2001 Sep 17;194(6):809-21</RefSource>
<PMID Version="1">11560996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2002 Mar;160(3):1057-68</RefSource>
<PMID Version="1">11891202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2007 Sep;40(3):102-13</RefSource>
<PMID Version="1">18062611</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2008 Jan;214(2):199-210</RefSource>
<PMID Version="1">18161745</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1326-34</RefSource>
<PMID Version="1">18203849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2008 Apr 1;180(7):5036-44</RefSource>
<PMID Version="1">18354229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 May 1;111(9):4571-9</RefSource>
<PMID Version="1">18310502</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2008 Aug 1;14(15):4961-70</RefSource>
<PMID Version="1">18676771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 10;26(32):5213-9</RefSource>
<PMID Version="1">18838709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2113-27</RefSource>
<PMID Version="1">18849330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2009 Apr;5(4):e1000371</RefSource>
<PMID Version="1">19360123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2009 Jul;16(7):1959-72</RefSource>
<PMID Version="1">19365624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2009 Aug;124(2):438-50</RefSource>
<PMID Version="1">19644258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int Arch Allergy Immunol. 2010;151(4):285-96</RefSource>
<PMID Version="1">19851071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Cell Physiol. 2010 Sep;299(3):C589-605</RefSource>
<PMID Version="1">20519446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Pract. 2000 Mar-Apr;8(2):65-71</RefSource>
<PMID Version="1">11898179</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):413-21</RefSource>
<PMID Version="1">12220554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 2002 Nov;137(11):1253-7</RefSource>
<PMID Version="1">12413312</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2002 Dec;979:197-210; discussion 229-34</RefSource>
<PMID Version="1">12543729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2003 Mar 17;197(6):687-701</RefSource>
<PMID Version="1">12642601</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2003 Apr 18;92(7):801-8</RefSource>
<PMID Version="1">12623882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2003 Jun 13;305(4):1002-7</RefSource>
<PMID Version="1">12767930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunopharmacol Immunotoxicol. 2003 May;25(2):235-57</RefSource>
<PMID Version="1">12784916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gene Med. 2003 Oct;5(10):839-51</RefSource>
<PMID Version="1">14533192</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2003 Nov;112(10):1486-94</RefSource>
<PMID Version="1">14617750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):586-90</RefSource>
<PMID Version="1">14699044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2004 Apr 9;279(15):15167-76</RefSource>
<PMID Version="1">14732719</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2004 Jun;11(6):573-80</RefSource>
<PMID Version="1">15172932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2004 Aug 1;173(3):2099-108</RefSource>
<PMID Version="1">15265946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Aug 5;351(6):552-9</RefSource>
<PMID Version="1">15295048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2004 Jun;37(2):73-91</RefSource>
<PMID Version="1">15328760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Matrix. 1989 Jan;9(1):68-71</RefSource>
<PMID Version="1">2710035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 1996 Feb;110(2):576-82</RefSource>
<PMID Version="1">8566606</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1996 Feb;148(2):527-37</RefSource>
<PMID Version="1">8579115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Dermatol. 1995 Sep-Oct;13(5):433-44</RefSource>
<PMID Version="1">8665454</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hand Surg Am. 1996 Mar;21(2):210-5</RefSource>
<PMID Version="1">8683048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1997 Aug 5;96(3):874-81</RefSource>
<PMID Version="1">9264495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 1998 Jan;110(1):47-51</RefSource>
<PMID Version="1">9424086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol Hepatol. 1998 Jul;13(7):680-4</RefSource>
<PMID Version="1">9715417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hypertension. 1998 Aug;32(2):273-9</RefSource>
<PMID Version="1">9719054</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2345-9</RefSource>
<PMID Version="1">10051644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 1999 Mar;177(3):184-7; discussion 188</RefSource>
<PMID Version="1">10219851</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1999 Sep;104(6):777-85</RefSource>
<PMID Version="1">10491413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cell Physiol. 2005 Apr;203(1):226-32</RefSource>
<PMID Version="1">15521071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jul 1;23(19):4312-21</RefSource>
<PMID Version="1">15994144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1402-10</RefSource>
<PMID Version="1">16648194</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2006 Jul;3(7):e254</RefSource>
<PMID Version="1">16834456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):841-6</RefSource>
<PMID Version="1">17175115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2007 Mar;117(3):524-9</RefSource>
<PMID Version="1">17332879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2007 Sep 15;120(4):982-91</RefSource>
<PMID Version="1">17805128</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042583" MajorTopicYN="N">Lymphangiogenesis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC2993295</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21056998</ArticleId>
<ArticleId IdType="pii">S0002-9440(10)62943-4</ArticleId>
<ArticleId IdType="doi">10.2353/ajpath.2010.100594</ArticleId>
<ArticleId IdType="pmc">PMC2993295</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Daluvoy, Sanjay" sort="Daluvoy, Sanjay" uniqKey="Daluvoy S" first="Sanjay" last="Daluvoy">Sanjay Daluvoy</name>
<name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name>
<name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name>
<name sortKey="Rockson, Stanley G" sort="Rockson, Stanley G" uniqKey="Rockson S" first="Stanley G" last="Rockson">Stanley G. Rockson</name>
<name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name>
<name sortKey="Zampell, Jaime" sort="Zampell, Jaime" uniqKey="Zampell J" first="Jaime" last="Zampell">Jaime Zampell</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002943 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002943 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:21056998 |texte= Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:21056998" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |